TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23730838

Group type: EXPERIMENTAL
Intervention: 420 mg silymarin three times a day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 700 mg silymarin three times a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19942469

Group type: EXPERIMENTAL
Intervention: Risedronate 75mg on 2 consecutive days a month (2CDM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate 5mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (historical control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate 5mg (historical control)
Number of subjects: 0
Study: 19095129

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 15888560

Group type: EXPERIMENTAL
Intervention: Subcutaneous ghrelin (3.6 nmol/kg)
Number of subjects: 9
Study: 11868007

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Epinephrine plus fibrin glue
Number of subjects: 135
Study: 10613617

Group type: EXPERIMENTAL
Intervention: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 AM
Number of subjects: 6

Group type: COMPARATOR
Intervention: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 PM
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (pre-dose measurements)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2 microg 1,25-dihydroxyvitamin D3 at both times
Number of subjects: 6
Study: 7604798

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 20
Study: 2235230

Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg of phospholipid per kilogram of body weight)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 100
Study: 843188

Group type: EXPERIMENTAL
Intervention: Methadone maintenance under open conditions
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Methadone maintenance under double blind conditions
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Rapid withdrawal at a rate of 10% of initial dose per week
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal at a rate of 3% of initial dose per week
Number of subjects: 127
Study: 31721368

Group type: EXPERIMENTAL
Intervention: Active exploration intervention (playing with and exploring blocks once a day for 8 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Book reading (control condition)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Active exploration intervention
Number of subjects: 59
Study: 29654893

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 732

Group type: COMPARATOR
Intervention: Doripenem
Number of subjects: 732
Study: 26505268

Group type: EXPERIMENTAL
Intervention: S‐technique (slow aspiration)
Number of subjects: 482

Group type: COMPARATOR
Intervention: R‐technique (rapid aspiration)
Number of subjects: 482
Study: 25511081

Group type: EXPERIMENTAL
Intervention: Strength-Balance-Cognitive (SBC) training
Number of subjects: 182
Study: 22590935

Group type: EXPERIMENTAL
Intervention: Glucose group receiving acetated Ringer's solution containing 1% glucose (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving acetated Ringer's solution without glucose (n = 10)
Number of subjects: 20
Study: 20083374

Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 10

Group type: COMPARATOR
Intervention: PDL (pulsed-dye laser)
Number of subjects: 10
Study: 18635183

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 10 days per month for 6 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ethinyl estradiol plus drospirenone
Number of subjects: 63
Study: 15876901

Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Buspirone 45 mg daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methadone taper
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 14551836

Group type: EXPERIMENTAL
Intervention: Lateral position technique with one assistant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position technique with two assistants
Number of subjects: 0
Study: 10692600

Group type: EXPERIMENTAL
Intervention: 5‐HT at 10(‐3) M
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5‐HT at 10(‐5) M
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study: 9058493

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (TTS 50, 50 micrograms/die)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/die)
Number of subjects: 22
Study: 8373213

Group type: EXPERIMENTAL
Intervention: FEM group (5‐FU, epirubicin (EPIR), and MMC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FAM group (5‐FU, adriamycin (ADM), and mitomycin C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FAM group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FEM group
Number of subjects: 15
Study: 3017401

Group type: EXPERIMENTAL
Intervention: 200 mg once daily for 5 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg once daily for 10 days
Number of subjects: 30
Study: 29678994

Group type: EXPERIMENTAL
Intervention: Exercise (supervised resistance and aerobic exercise performed three times per week for the first 6 months, transitioning to once a week for months 7-12, and self-managed from months 13-36)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 168
Study: 26626806

Group type: EXPERIMENTAL
Intervention: Independent gait analysis insole with strict 20 kg partial weight bearing for 6 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gait analysis parameters (load, activity, gait time over 20 kg weight bearing, maximum ground reaction force)
Number of subjects: 10
Study: 25454414

Group type: EXPERIMENTAL
Intervention: FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) alternating with fixed-dose rate gemcitabine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Fixed-dose rate gemcitabine alone
Number of subjects: 98
Study: 22283640

Group type: EXPERIMENTAL
Intervention: OmniPod system
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional CSII
Number of subjects: 29
Study: 20299189

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 400 mg
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 18403189

Group type: EXPERIMENTAL
Intervention: 1.8 g eicosapentaenoic acid (EPA) plus 0.3 g docosahexaenoic acid (DHA) per day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15707563

Group type: EXPERIMENTAL
Intervention: Female condom (FC)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Male condom (MC)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 400
Study: 11239530

Group type: COMPARATOR
Intervention: Diane 35 (2 mg of cyproterone acetate and 35 microg of ethinyl estradiol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diane 35 plus finasteride (5 mg daily)
Number of subjects: 40
Study: 9895419

Group type: EXPERIMENTAL
Intervention: GOS (galacto-oligosaccharides) 9 g daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (2 control yoghurts daily)
Number of subjects: 14
Study: 8049922

Group type: EXPERIMENTAL
Intervention: Risk score based on age, shock, myocardial disease, cerebrovascular disease, renal disease.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Rupture
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Shock
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Myocardial disease
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cerebrovascular disease
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Renal disease
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Size of the aneurysm
Number of subjects: 500
Study: 3051991

Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained-release preparation, titrated from 240 to 360 mg/day in a twice-daily regimen)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 8160593

Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 230

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 230
Study: 101315

Group type: EXPERIMENTAL
Intervention: Orally administered sodium cromoglycate (400 mg to 600 mg, four times daily)
Number of subjects: 5
Study: 30614138

Group type: EXPERIMENTAL
Intervention: Low-flow induction (Group L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard induction (Group S)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 27648821

Group type: EXPERIMENTAL
Intervention: FD‐Y0007
Number of subjects: 66

Group type: COMPARATOR
Intervention: Coagrasper
Number of subjects: 66
Study: 26362496

Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control (voluntary status via Section 17 leave)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CTO experience
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CTOs
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control
Number of subjects: 336
Study: 23683683

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pelvic exercises
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 21817820

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (≤ 30 ml/kg) followed by crystalloid infusion
Number of subjects: 106

Group type: COMPARATOR
Intervention: Crystalloid only
Number of subjects: 106
Study: 19531646

Group type: EXPERIMENTAL
Intervention: Empirical data from rats, sheep, and humans
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Computer simulations of pulsatile LH profiles
Number of subjects: 156
Study: 17954796

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) providing balanced, quantitative information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard information available from the screening program (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 0
Study: 15234290

Group type: EXPERIMENTAL
Intervention: Farnsworth-Munsell 100-hue test
Number of subjects: 2701

Group type: COMPARATOR
Intervention: Deferred-treatment group
Number of subjects: 2701

Group type: COMPARATOR
Intervention: Immediate-treatment group
Number of subjects: 2701
Study: 11802511

Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 45
Study: 9741505

Group type: EXPERIMENTAL
Intervention: Accelerated t-PA regimen
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Infarct related artery (RCA/Lcx vs. LAD)
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Body weight
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: History of smoking
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Time from symptom onset to treatment
Number of subjects: 1030
Study: 8064454

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg plus codeine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2908306

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31974637

Group type: EXPERIMENTAL
Intervention: Becker Muscular Dystrophy (BMD) patients
Number of subjects: 20
Study: 31056855

Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasted condition (reference)
Number of subjects: 0
Study: 30299482

Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cystectomy (Group 1)
Number of subjects: 60
Study: 29738180

Group type: EXPERIMENTAL
Intervention: Novel disposable ring (DR group)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Suture device (SD group)
Number of subjects: 470
Study: 25933197

Group type: EXPERIMENTAL
Intervention: Olive Oil (OO) 3 g/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) 3 g/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (naive)
Number of subjects: 42
Study: 24089026

Group type: EXPERIMENTAL
Intervention: Supine lithotomy position (group A)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Prone position (group B)
Number of subjects: 109
Study: 21129866

Group type: EXPERIMENTAL
Intervention: Oral and intravenous bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toremifene and denosumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone mineral density (BMD) testing by dual energy X-ray absorptiometry (DXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Forearm DXA
Number of subjects: 0

Group type: COMPARATOR
Intervention: FRAX or another risk calculator
Number of subjects: 0
Study: 19268266

Group type: EXPERIMENTAL
Intervention: Diosmectite (6 g/day for children 1-12 months; 12 g/day for children 13-36 months)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Diosmectite
Number of subjects: 602
Study: 17316925

Group type: EXPERIMENTAL
Intervention: 17DD vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHO 17D-213/77 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of yellow fever and measles-mumps-rubella vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibodies
Number of subjects: 0
Study: 15308998

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 1356
Study: 11672549

Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen Lo
Number of subjects: 2894

Group type: COMPARATOR
Intervention: Loestrin Fe 1/20
Number of subjects: 2894
Study: 9877264

Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8066937

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2662884

Group type: EXPERIMENTAL
Intervention: sodium‐meglumine ioxaglate
Number of subjects: 20

Group type: COMPARATOR
Intervention: iopromide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sodium‐meglumine ioxaglate and iopromide
Number of subjects: 20
Study: 30578396

Group type: EXPERIMENTAL
Intervention: Musical intervention group (received a musical intervention and visual deprivation during the first 30 minutes of each NIV session)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sensory deprivation group (wore insulating headphones and visual deprivation during the first 30 minutes of each NIV session)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (received NIV as routinely performed)
Number of subjects: 113
Study: 27838777

Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25520278

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at bilateral ST36 and PC6 points
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia without EA stimulation
Number of subjects: 40
Study: 22921765

Group type: EXPERIMENTAL
Intervention: DTMS after brief exposure to the traumatic event with the script‐driven imagery procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: DTMS after brief exposure to a non‐traumatic event
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation after brief exposure to the traumatic event
Number of subjects: 30
Study: 21963002

Group type: EXPERIMENTAL
Intervention: Stratified primary care management
Number of subjects: 1573

Group type: COMPARATOR
Intervention: Current best practice (non-stratified care)
Number of subjects: 1573
Study: 18828141

Group type: EXPERIMENTAL
Intervention: MoodGYM
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (usual curriculum)
Number of subjects: 157
Study: 17122137

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VEGF Trap
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15579782

Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione t.i.d. for 28 days
Number of subjects: 20
Study: 11736743

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: All groups (pHF, eHF, BF)
Number of subjects: 72
Study: 9015054

Group type: EXPERIMENTAL
Intervention: Plastic-covered stent placement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Uncovered stent placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 60
Study: 8095980

Group type: EXPERIMENTAL
Intervention: Zidovudine (BW-02 study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine (ACTG-002 study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 2946277

Group type: EXPERIMENTAL
Intervention: 3 monthly doses of 2 micrograms vaccine mixed with adjuvant subcutaneously (Institut Pasteur Production‐Hevac B)
Number of subjects: 125

Group type: COMPARATOR
Intervention: 3 doses of 2 micrograms non‐adjuvated vaccine intradermally given 1 month apart
Number of subjects: 125
Study: 31548184

Group type: EXPERIMENTAL
Intervention: Zoliflodacin
Number of subjects: 199
Study: 29452816

Group type: COMPARATOR
Intervention: Low-flow 100% oxygen at 0.2 litres kg-1 min-1 (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: THRIVE 100% oxygen at 2 litres kg-1 min-1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: THRIVE 30% oxygen at 2 litres kg-1 min-1
Number of subjects: 60
Study: 27382591

Group type: EXPERIMENTAL
Intervention: Orem's self-care model-based training (8 sessions of 2 hours each)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 24387842

Group type: EXPERIMENTAL
Intervention: Novamin 18 AAs (2 mL/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine (0.5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol (1 mg/kg)
Number of subjects: 60
Study: 22542094

Group type: COMPARATOR
Intervention: Intervention from randomized trials (NET‐PD FS1 and FS‐TOO)
Number of subjects: 413
Study: 19631856

Group type: EXPERIMENTAL
Intervention: Treatment delivered after occurrence of dental trauma
Number of subjects: 0
Study: 17435407

Group type: EXPERIMENTAL
Intervention: Skin rehabilitation massage therapy (SRMT) for 3 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Skin rehabilitation massage therapy (SRMT)
Number of subjects: 18
Study: 15561449

Group type: EXPERIMENTAL
Intervention: PPA gum
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 439
Study: 11956968

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 555

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 555
Study: 9863744

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoated aspirin
Number of subjects: 20
Study: 8567566

Group type: EXPERIMENTAL
Intervention: Pre-triathlon DLCO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post-triathlon DLCO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pre-triathlon KCO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post-triathlon KCO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pre-triathlon mean lung density
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post-triathlon mean lung density
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post-triathlon number of polygonal and linear opacities
Number of subjects: 8
Study: 1637604

Group type: EXPERIMENTAL
Intervention: Etomidate in propylene glycol (EtoPG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Etomidate in lipid emulsion (EtoLip)
Number of subjects: 12
Study: 6375703

Group type: EXPERIMENTAL
Intervention: iohexol 350 (Omnipaque)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Urografin 370
Number of subjects: 25
Study: 31154313

Group type: EXPERIMENTAL
Intervention: Providing peer reviewers with a summary of registered, pre‐specified primary trial outcomes during the intervention phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control phase where peer reviewers do not receive registry information.
Number of subjects: 0
Study: 29923299

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 3 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 26685074

Group type: EXPERIMENTAL
Intervention: CVP-guided hydration group (n = 132)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Standard hydration group (n = 132)
Number of subjects: 264
Study: 25372085

Group type: EXPERIMENTAL
Intervention: Rituximab (500 mg on days 0 and 14, and at months 6, 12, and 18)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Azathioprine (daily until month 22)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 115

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 115